Navigation Links
AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Date:9/17/2008

QUEBEC CITY, Sept. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Financial Officer, Dennis Turpin, CA, will present a company overview at the upcoming CIBC World Markets 7th Annual Eastern Investor Conference on Tuesday, September 23, 2008 at 3:25 pm (eastern time), at the Centre Sheraton Hotel in Montreal, Canada.

A live webcast of the presentation will be available on AEterna Zentaris' website at http://www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
2. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
3. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
4. AEterna Zentaris Sells Quebec City Building for $7.1 million
5. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
6. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
9. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
10. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):